Application of acetagastrodine in preparing medicines to prevent and treat vascular dementia (VD) and Alzheimer disease (AD)
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of acetylgastrodin and vascular dementia, applied in the field of medicine, can solve the problems that acetylgastrodin has no research reports on the prevention and treatment of senile dementia
Inactive Publication Date: 2011-09-21
KPC PHARM INC
View PDF2 Cites 15 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0007] The preventive and therapeutic effects of acetyl
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0034] Embodiment 1: the preparation of acetylgastrodin capsule
[0035] Prescription (1000 capsules):
[0036] Contents:
[0037] Acetylgastrodin 30g
[0038] soybean oil 100g
[0039] Capsule:
[0040] Gelatin 60.2g
[0041] Glycerin 19.8g
[0042] Appropriate amount of water
[0043] Ethylparaben (ethylparaben) 0.12g
[0044] Preparation method: Take acetylgastrodin, add it to soybean oil, stir to dissolve it completely, press soft capsules, dry, make 1000 capsules, and obtain a product with a specification of 30mg.
Embodiment 2
[0045] Embodiment 2: the preparation of acetylgastrodin soft capsule
[0046] Prescription (1000 capsules):
[0047] Contents:
[0048] Acetylgastrodin 200g
[0049] Corn Oil 200g
[0050] Capsule:
[0051] Gelatin 60.2g
[0052] Glycerin 19.8g
[0053] Appropriate amount of water
[0054] Ethylparaben (ethylparaben) 0.12g
[0055] Preparation method: Take acetylgastrodin, add it to corn oil, stir to dissolve it completely, press soft capsules, dry, make 1000 capsules, and obtain a product with a specification of 200mg.
Embodiment 3
[0056] Embodiment 3: the preparation of acetylgastrodin soft capsule
[0057] Prescription (1000 capsules):
[0058] Contents:
[0059] Acetyl Gastrodin 500g
[0060] α-linolenic acid 1000g
[0061] Capsule:
[0062] Gelatin 60.2g
[0063] Glycerin 19.8g
[0064] Appropriate amount of water
[0065] Ethylparaben (ethylparaben) 0.12g
[0066] Preparation method: Take acetylgastrodin, add it to peanut oil, stir to dissolve it completely, press soft capsules, dry, make 1000 capsules, and obtain a product with a specification of 500mg.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
Relating to the medicine field, the invention discloses the use of acetagastrodine in preparing medicines to prevent and treat vascular dementia and Alzheimer disease. The invention also provides a medicinal composition for preventing and treating senile dementia and its capsule as well as sustained release agent. Animal tests show that: acetagastrodine can substantially enhance the learning and memory abilities of rats with vascular dementia, reduce the activity of AchE in brains, enhance the vitality of ChAT in brains, and remarkably reduce Glu content; acetagastrodine has significant protective effect on damaged PC12 cells caused by H2O2 by enhancing the vitality of SOD and total ATP enzyme in PC12 cells and reducing the content of MDA and LD; acetagastrodine can substantially enhance the learning and memorizing abilities of AD model rats, enhance the CAT content in brains of the model rats, reduce the MAO vitality and simultaneously prevent the decrease of neurotransmitters. Acetagastrodine is better than gastrodin in terms of the treatment effects on VD and AD, and enjoys good clinical application prospect.
Description
technical field [0001] The invention relates to the field of medicine, in particular to the new application of acetylgastrodin in the preparation of drugs for preventing and treating vascular dementia and Alzheimer's disease. Background technique [0002] Alzheimer's disease is a mental impairment syndrome that occurs in the early and old age and is characterized by brain dysfunction characterized by progressive dementia. Including senile dementia, also known as Alzheimer's disease (Alzheimerdisease, AD for short) and cerebrovascular dementia (Vascular dementia, VD for short). Among them, AD is a primary central nervous system degenerative disease that occurs in middle-aged and elderly people; VD is dementia caused by brain damage caused by cerebrovascular disease. The etiology of VD involves two aspects, namely, cerebrovascular disease and risk factors. Risk factors include risk factors for cerebrovascular disease (hypertension, hyperlipidemia, heart disease, diabetes, co...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more